Department of Clinical Pharmacy Laboratory, University of Ibadan
Ibadan, Oyo State, 200284, Nigeria
Completed
NCT Number: NCT04339283
Effect of Standardized Hibiscus Sabdariffa Tea in Seemingly Healthy Human Volunteers
Hibiscus sabdariffa tea is commonly used all over the world by healthy individual but the tea is also employed by patients in the management of chronic diseases such as hypertension diabetes, high cholesterol, liver disease etc. Several studies in humans and animal have proved the efficacy of Hibiscus sabdariffa tea in lowering blood pressure, blood glucose level and serum total cholesterol. But no study exists on the effect of daily consumption of this tea on blood pressure, blood glucose, total cholesterol and other biochemical and hematological parameters in healthy humans. Hence this study.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–40 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
About this study
Several studies have been carried out on the effect of the water beverage of Hibiscus sabdariffa, most focus on hypertensive patients, diabetic patients and obese patient and some studies investigated the hypolipidemic a effect of the water beverage of Hibiscus sabdariffa as well as its effect on haematological parameters but mice were used for these studies. Little or no investigation has been done to assess the safety of daily consumption of this water beverage of hibiscus sabdariffa on humans.
Hence, this study aims at investigating the safety in the daily consumption of Zobo in humans, monitoring lipid profile, blood pressure, blood glucose, body mass index and haematological parameters such as haematocrit, haemoglobin, total white blood cells and also hepatic indices.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy volunteers only
- Not on any medications or herbs
- No disease condition
- Females not pregnant
- Non-smokers
Exclusion criteria
- Below 18yrs or above 40 years
- presence of chronic disease
- on medications pregnant females
Treatment and study plan
Standardized Hibiscus sabdariffa tea
Dietary SupplementDaily consumption of Standardized Hibiscus sabdariffa tea
Primary outcomes
-
Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure on the 14th day
Time frame: 14 days
Blood pressure was measured in mmHg at baseline and on the 14th day of study with the aid of Omron Digital Blood pressure monitor
-
Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure on the 28th day
Time frame: 28 days
Systolic and Diastolic Blood pressures were measured in mmHg at baseline and on the 28th day of study with the aid of Omron Digital Blood pressure monitor
-
Change from Baseline Fasting Blood Glucose level on the 14th day
Time frame: 14 days
Fating blood glucose level was measured with AccuChek Active glucometer in mg/dL on the 14th day of study
-
Change from Baseline Fasting Blood Glucose level on the 28th day
Time frame: 28 days
Fating blood glucose level was measured with AccuChek Active glucometer in mg/dL on the 28th day of study
-
Change from Baseline Total Serum Cholesterol on the 14th day
Time frame: 14 days
Total Serum Cholesterol was analysed with Randox kit and measured in mg/dL on the 14th day
-
Change from Baseline Total Serum Cholesterol on the 28th day
Time frame: 28 days
Total Serum Cholesterol was analysed with Randox kit and measured in mg/dL on the 28th day
-
Change from Baseline Triglyceride on the 14th day
Time frame: 14 days
Triglyceride was analysed with Randox kit and measured in mg/dL on the 14th day
-
Change from Baseline Triglyceride on the 28th day
Time frame: 28 days
Triglyceride was analysed with Randox kit and measured in mg/dL on the 28th day
-
Change from Baseline High Density Lipoprotein Cholesterol on the 14th day
Time frame: 14 days
High Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 14th day
-
Change from Baseline High Density Lipoprotein Cholesterol on the 28th day
Time frame: 28 days
High Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 28th day
-
Change from Baseline Low Density Lipoprotein Cholesterol on the 14th day
Time frame: 14 days
Low Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 14th day
-
Change from Baseline Low Density Lipoprotein Cholesterol on the 28th day
Time frame: 28 days
Low Density Lipoprotein Cholesterol was analysed with Randox kit and measured in mg/dL on the 28th day
-
Change form Baseline Alanine Aminotransferase on the 14th day
Time frame: 14 days
Alanine aminotransferase was analysed with Randox kit and measured in U/L on the 14th day
-
Change form Baseline Alanine Aminotransferase on the 28th day
Time frame: 28 days
Alanine aminotransferase was analysed with Randox kit and measured in U/L on the 28th day
-
Change form Baseline Aspartate Aminotransferase on the 14th day
Time frame: 14 days
Aspartate aminotransferase was analysed with Randox kit and measured in U/L on the 14th day
-
Change form Baseline Aspartate Aminotransferase on the 28th day
Time frame: 28 days
Aspartate aminotransferase was analysed with Randox kit and measured in U/L on the 28th day
-
Change form Baseline Blood Urea Nitrogen on the 14th day
Time frame: 14 days
Blood Urea Nitrogen was analysed with Randox kit and measured in mg/dL on the 14th day
-
Change form Baseline Blood Urea Nitrogen on the 28th day
Time frame: 28 days
Blood Urea Nitrogen was analysed with Randox kit and measured in mg/dL on the 28th day
-
Change form Baseline Serum Creatinine on the 14th day
Time frame: 14 days
Serum Creatinine was analysed with Randox kit and measured in mg/dL on the 14th day
-
Change form Baseline Serum Creatinine on the 28th day
Time frame: 28 days
Serum Creatinine was analysed with Randox kit and measured in mg/dL on the 28th day
-
Change form Baseline Albumin on the 14th day
Time frame: 14 days
Albumin was analysed with Randox kit and measured in g/dL on the 14th day
-
Change form Baseline Albumin on the 28th day
Time frame: 28 days
Albumin was analysed with Randox kit and measured in g/dL on the 28th day
-
Change form Baseline Hematocrit on the 14th day
Time frame: 14 days
Hematocrit was analysed in the laboratory and measured in % on the 14th day
-
Change form Baseline Hematocrit on the 28th day
Time frame: 28 days
Hematocrit was analysed in the laboratory and measured in % on the 28th day
-
Change form Baseline Hemoglobin on the 14th day
Time frame: 14 days
Hemoglobin was analysed in the laboratory and measured in g/dL on the 14th day
-
Change form Baseline Hemoglobin on the 28th day
Time frame: 28 days
Hemoglobin was analysed in the laboratory and measured in g/dL on the 28th day
-
Change form Baseline White Blood Cell count on the 14th day
Time frame: 14 days
White Blood Cell counts was analysed in the laboratory and measured in 10*3/ µL on the 14th day
-
Change form Baseline White Blood Cell count on the 28th day
Time frame: 28 days
White Blood Cell counts was analysed in the laboratory and measured in 10*3/ µL on the 28th day
-
Change form Baseline Total Protein on the 14th day
Time frame: 14 days
Total Protein was analysed in the laboratory and measured in g/dL on the 14th day
-
Change form Baseline Total Protein on the 28th day
Time frame: 28 days
Total Protein was analysed in the laboratory and measured in g/dL on the 28th day
-
Change form Baseline Pulse on the 14th day
Time frame: 14 days
Pulse was measured with the BP monitor in /min on the 14th day
-
Change form Baseline Pulse on the 28th day
Time frame: 28 days
Pulse was measured with the BP monitor in /min on the 28th day
Secondary outcomes
-
Change from Baseline Body Mass Index on the 14th day
Time frame: 14 day
Body mass index measure in kg/sq m was calculated from a measure of weight in kg and height in meters on the 14 day
-
Change from Baseline Body Mass Index on the 28th day
Time frame: 28 day
Body mass index measure in kg/sq m was calculated from a measure of weight in kg and height in meters on the 14 day
Sponsors and collaborators
Lead sponsor
University of Ibadan
Other
Registry information
Official study title
Standardized Hibiscus Sabdariffa Linn Tea, Potential Nutraceutical Candidate for the Prevention of Hypertension, Diabetes, and Hypercholesterolemia - a Pilot Study
Important dates
- Study start
- 2019
- Primary completion
- 2019
- Study completion
- 2019
- First posted
- Apr 9, 2020
- Registry last updated
- Apr 9, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses
NCT02219438
Healthy Human Volunteers
San Diego, California, United States
View Trial Details
Completed
Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers
NCT00813670
Healthy Human Volunteers
Montreal, Quebec, Canada
View Trial Details
Completed
Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers
NCT00765427
Healthy Human Volunteers
Toronto, Ontario, Canada
View Trial Details
Recruiting
"One All" to Get it RYT (Resilient Young Tribal Adults)
NCT06474260
Behavior, Healthy Human Volunteers
Chamrajnagar, Karnataka, India
View Trial Details